[HTML][HTML] Development and validation of a new tumor-based gene signature predicting prognosis of HBV/HCV-included resected hepatocellular carcinoma patients
GQ Zhu, Y Yang, EB Chen, B Wang, K Xiao… - Journal of translational …, 2019 - Springer
Background Due to the phenotypic and molecular diversity of hepatocellular carcinomas
(HCC), it is still a challenge to determine patients' prognosis. We aim to identify new …
(HCC), it is still a challenge to determine patients' prognosis. We aim to identify new …
[HTML][HTML] Development and validation of a new tumor-based gene signature predicting prognosis of HBV/HCV-included resected hepatocellular carcinoma patients
GQ Zhu, Y Yang, EB Chen, B Wang, K Xiao… - Journal of …, 2019 - ncbi.nlm.nih.gov
Background Due to the phenotypic and molecular diversity of hepatocellular carcinomas
(HCC), it is still a challenge to determine patients' prognosis. We aim to identify new …
(HCC), it is still a challenge to determine patients' prognosis. We aim to identify new …
Development and Validation of a New Tumor-Based Gene Signature Predicting Prognosis of HBV/HCV-Included Resected Hepatocellular Carcinoma Patients
GQ Zhu, Y Yang, EB Chen, B Wang, K Xiao, SM Shi… - 2018 - papers.ssrn.com
Background: Due to the phenotypic and molecular diversity of hepatocellular carcinomas
(HCC), it is a challenge to determine patients' prognosis. We intent to identify new …
(HCC), it is a challenge to determine patients' prognosis. We intent to identify new …
Development and validation of a new tumor-based gene signature predicting prognosis of HBV/HCV-included resected hepatocellular carcinoma patients.
GQ Zhu, Y Yang, EB Chen, B Wang… - Journal of …, 2019 - search.ebscohost.com
Abstract < bold> Background: </bold> Due to the phenotypic and molecular
diversity of hepatocellular carcinomas (HCC), it is still a challenge to determine patients' …
diversity of hepatocellular carcinomas (HCC), it is still a challenge to determine patients' …
[HTML][HTML] Development and validation of a new tumor-based gene signature predicting prognosis of HBV/HCV-included resected hepatocellular carcinoma patients
GQ Zhu, Y Yang, EB Chen… - Journal of …, 2019 - … -medicine.biomedcentral.com
Due to the phenotypic and molecular diversity of hepatocellular carcinomas (HCC), it is still
a challenge to determine patients' prognosis. We aim to identify new prognostic markers for …
a challenge to determine patients' prognosis. We aim to identify new prognostic markers for …
Development and validation of a new tumor-based gene signature predicting prognosis of HBV/HCV-included resected hepatocellular carcinoma patients.
GQ Zhu, Y Yang, EB Chen, B Wang, K Xiao… - Journal of …, 2019 - europepmc.org
Background Due to the phenotypic and molecular diversity of hepatocellular carcinomas
(HCC), it is still a challenge to determine patients' prognosis. We aim to identify new …
(HCC), it is still a challenge to determine patients' prognosis. We aim to identify new …
Development and validation of a new tumor-based gene signature predicting prognosis of HBV/HCV-included resected hepatocellular carcinoma patients
GQ Zhu, Y Yang, EB Chen, B Wang, K Xiao… - Journal of …, 2019 - go.gale.com
Background Due to the phenotypic and molecular diversity of hepatocellular carcinomas
(HCC), it is still a challenge to determine patients' prognosis. We aim to identify new …
(HCC), it is still a challenge to determine patients' prognosis. We aim to identify new …
Development and validation of a new tumor-based gene signature predicting prognosis of HBV/HCV-included resected hepatocellular carcinoma patients
GQ Zhu, Y Yang, EB Chen, B Wang… - Journal of …, 2019 - pubmed.ncbi.nlm.nih.gov
Background Due to the phenotypic and molecular diversity of hepatocellular carcinomas
(HCC), it is still a challenge to determine patients' prognosis. We aim to identify new …
(HCC), it is still a challenge to determine patients' prognosis. We aim to identify new …
Development and validation of a new tumor-based gene signature predicting prognosis of HBV/HCV-included resected hepatocellular carcinoma patients
GQ Zhu, Y Yang, EB Chen, B Wang, K Xiao… - Journal of Translational …, 2019 - infona.pl
Background Due to the phenotypic and molecular diversity of hepatocellular carcinomas
(HCC), it is still a challenge to determine patients' prognosis. We aim to identify new …
(HCC), it is still a challenge to determine patients' prognosis. We aim to identify new …
Development and validation of a new tumor-based gene signature predicting prognosis of HBV/HCV-included resected hepatocellular carcinoma patients
Z Gui-Qi, Y Yang, C Er-Bao, B Wang… - Journal of …, 2019 - search.proquest.com
Background Due to the phenotypic and molecular diversity of hepatocellular carcinomas
(HCC), it is still a challenge to determine patients' prognosis. We aim to identify new …
(HCC), it is still a challenge to determine patients' prognosis. We aim to identify new …